Marksans Pharma

    MARKSANS
    Pharma
    ₹294.50
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹13,347 Cr

    P/E
    23.85
    Day range
    ₹291.30 – ₹315.55
    52-week range
    ₹155.00 – ₹350.95
    Volume
    14.14 L
    Open
    ₹306.20
    Prev close
    ₹306.10

    Latest results · Q2 FY27(consolidated)Revenue ₹940 Cr+30.5%Profit ₹144 Cr+44.8%Margin 15.3%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 64 / 100

    Factor percentiles

    Value61
    Quality63
    Momentum75
    Low volatility57

    Derived metrics

    Earn. yield
    4.2%
    Graham no.
    ₹139.57
    vs Graham
    -52.6%
    ROE ÷ P/B
    3.6%
    12-1 mom.
    +66.3%
    Return / vol
    1.37
    Magic Formula
    #162
    Piotroski
    4/6
    FCF yield
    2.5%
    PEG
    0.53

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Marksans PharmaMARKSANS₹13,347 Cr23.854.2015.3%19.0%23.0%0.14+30.6%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2h ago

    Headlines about Marksans Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    25.0
    Price / Book
    4.01
    ROE (FY26)
    15.3%
    ROCE (latest year)
    19%
    Dividend yield
    0.29%

    Moving averages (NSE)

    20-day
    ₹305.67
    Price below
    50-day
    ₹317.07
    Price below
    200-day
    ₹248.13
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +16.8%
    Profit 3Y CAGR
    +16.6%
    Revenue YoY (Sep 2026)
    +30.6%
    Profit YoY (Sep 2026)
    +45.5%
    Operating margin
    23.0%
    Net margin
    15.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr250 Cr500 Cr750 Cr1K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-400 Cr-200 Cr0 Cr200 Cr400 Cr600 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY20FY21FY22FY23FY24FY25₹0₹0.2₹0.4₹0.6

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales586560591642682708620720754856841940
    Expenses453450462495543582520576594661628726
    Operating Profit133110128147139127100144161195213214
    OPM %23%20%22%23%20%18%16%20%21%23%25%23%
    Other Income517150281562220352518
    Interest353333666677
    Depreciation222120202123232724242532
    Profit before tax11310012012514311677133151200207194
    Tax %26%23%26%22%27%22%24%26%25%25%23%26%
    Net Profit83788998105915899114149159144
    EPS in Rs₹1.84₹1.73₹1.96₹2.13₹2.31₹2.00₹1.29₹2.17₹2.50₹3.27₹3.47₹3.12

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days80

    +8 days since Mar 2021

    Inventory Days278

    +30 days since Mar 2021

    Days Payable96

    -7 days since Mar 2021

    Cash Conversion Cycle261

    +44 days since Mar 2021

    Working Capital Days149

    +45 days since Mar 2021

    Strengths, risks & growth

    Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

    Compounded Sales Growth

    10 Years
    +13%
    5 Years
    +16%
    3 Years
    +17%
    TTM
    +24%

    Compounded Profit Growth

    10 Years
    +18%
    5 Years
    +12%
    3 Years
    +16%
    TTM
    +59%

    Stock Price CAGR

    10 Years
    +22%
    5 Years
    +40%
    3 Years
    +30%
    1 Year
    +58%

    Return on Equity

    10 Years
    +17%
    5 Years
    +17%
    3 Years
    +16%
    Last Year
    +15%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter43.87%43.87%43.87%43.87%0.00 pp
    FII8.13%16.76%17.47%19.06%+1.59 pp
    DII5.91%6.57%6.19%5.54%-0.65 pp
    Public42.08%32.78%32.46%31.53%-0.93 pp

    Filed with NSE for Sept 2026: promoters 43.87%, public 56.13%

    Analysts & fund holdings

    100%
    100% recommend buy
    3 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E23.8 vs 45.2
    Sector P/B6.05
    Beta1.43

    Who holds the shares, quarter by quarter

    Mutual funds 3.72% (-0.64 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters43.9%
    • Foreign institutions19.1%
    • Mutual funds3.7%
    • Insurance0.0%
    • Other domestic institutions1.8%
    • Retail23.4%
    • Others8.1%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Bandhan Small Cap Fund0.75%0.30%-0.02 pp
    UTI Small Cap Fund0.69%1.92%+0.47 pp
    Kotak MNC Fund0.44%2.91%+0.60 pp
    Kotak Special Opportunities Fund0.36%2.60%-0.48 pp
    UTI Large & Mid Cap Fund0.28%0.65%-0.15 pp

    Scorecard

    Performance
    High
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    42.1%
    Downside volatility
    33.9%
    Worst 5% of days
    3.3%
    Average of that tail
    4.7%
    Max drawdown (1Y)
    20.3%
    Below its peak
    15.3%

    Against the market

    Beta vs Nifty 50
    1.00
    Correlation
    0.32
    Relative strength (3M)
    -15.0%
    ATR (14)
    4.5%

    Return

    Return 1M
    -5.3%
    Return 3M
    -11.1%
    Return 6M
    +35.3%
    Return 1Y
    +57.5%
    vs 200-day average
    +18.7%

    Momentum

    RSI (14)
    41.9
    MACD histogram
    -0.19
    Stochastic %K
    8.6
    ADX (14)
    13.9
    +DI / −DI
    16.3 / 24.7
    Money flow index
    44.5

    Participation

    Delivery (20d avg)
    45.3%
    vs its 60-day baseline
    +3.7 pts
    Volume vs 20-day
    -0.1σ
    Close vs day's VWAP
    -2.3%
    52-week position
    72 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹328 Cr
    FCF yield
    2.5%
    Cash conversion
    1.09
    Accruals ratio
    -0.010
    Net debt
    -₹277 Cr
    Net debt / equity
    -0.08
    EV / sales
    3.85
    PEG
    0.53
    Capex intensity
    4.4%
    Revenue CAGR
    459.6%
    Profit CAGR
    529.1%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    No market trades
    3 buys · ₹0
    1 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Sandra Saldanha
    Director · Gift
    Sell2,28,273₹017 Sept 2026
    Schenelle Megan Saldanha
    Directors Immediate Relative · Gift
    Buy1,45,000₹017 Sept 2026
    Marise Ann Saldanha
    Directors Immediate Relative · Gift
    Buy20,000₹017 Sept 2026
    Merrill Jean Saldanha
    Directors Immediate Relative · Gift
    Buy63,273₹017 Sept 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.90 Per Share

      20 Aug 2026
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.80 Per Share

      1 Aug 2025
      ex-date
    • dividend
      ₹0.60

      Dividend - Rs 0.60 Per Share

      17 Sept 2024
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.50 Per Share

      7 Jun 2023
      ex-date
    • dividend
      ₹0.25

      Annual General Meeting/Dividend - Rs 0.25 Per Share

      19 Aug 2022
      ex-date
    • dividend
      ₹0.25

      Annual General Meeting/Dividend - Rs 0.25 Per Share

      15 Sept 2021
      ex-date
    • other
      Not available — not reported in this filing

      Extra-Ordinary General Meeting

      1 Jul 2021
      ex-date
    • dividend
      ₹0.10

      Annual General Meeting/Dividend - Rs 0.10 Per Share

      22 Sept 2020
      ex-date
    • dividend
      ₹0.05

      Annual General Meeting/Dividend - Rs 0.05 Per Share

      19 Sept 2019
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend Re 0.05 Per Share

      19 Sept 2018
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.05 Per Share

      19 Sept 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 0.12 Per Share

      22 Sept 2016
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/ Dividend - Re 0.12/- Per Share

      23 Sept 2015
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting / Dividend - Re 0.10/- Per Share

      18 Sept 2014
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      19 Sept 2013
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      20 Sept 2012
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2011
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2010
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      17 Sept 2009
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Sept 2008
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of Investors/Analyst meet on Q2 FY27 Financial Results

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication for Unaudited Financial Results for the quarter and half year ended September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release for Financial Results Q2FY27

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation Q2FY27

    Result
    Financial Results For The Quarter And Half Year Ended 30 September 2026

    Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026

    Board Meeting
    Board Meeting Outcome for Board Meeting Outcome For Board Meeting Outcome For The Board Meeting Held On 04 November 2026

    Please find attached outcome of the Board meeting held on 04 November 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of schedule for Q2FY27 Earnings Conference Call

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026

    Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Unaudited Financial Results ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter and half year ended September 30, 2026

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window for the quarter and half year ended 30 September, 2026

    Company Update
    Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares

    Notice to Shareholders regarding re-opening of Special Window for Re-lodgement of transfer requests of Physical Shares

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of schedule of Investors Meet

    Filed with BSE (scrip 524404); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Regulatory orders

    • Order

      Order in the matter of Marksans Pharma Limited.

      5 Mar 2021
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of three entities in the matter of Marksans Pharma Ltd.

      31 Oct 2018
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of six entities in the matter of Marksans Pharma Ltd.

      31 Oct 2018
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Pereira Sebestian Ruzario in the matter of Marksans Pharma Ltd

      31 Oct 2018
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Aparna G Joshi in the matter of Marksans Pharma Limited

      26 Sept 2018
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Marksans Pharma: common questions

    Answered from the figures on this page.

    Marksans Pharma last traded at ₹294.50 (NSE, as of 18 Nov 2026). The last session moved it down 3.79%.

    Marksans Pharma is valued at about ₹13,347 crore (NSE, as of 18 Nov 2026).

    Marksans Pharma trades at a price-to-earnings ratio of 23.85 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Marksans Pharma has traded between ₹155.00 and ₹350.95 over the past 52 weeks, to 18 Nov 2026. It is currently 71% of the way up that range.

    Marksans Pharma (MARKSANS) is classified under Pharma on this site's screener.